Home / Generics / General / FDA significantly increases generic user fees in 2019

FDA significantly increases generic user fees in 2019 Posted 07/09/2018

The US Food and Drug Administration (FDA) has increased the amount that generics manufacturers will have to pay for large-size operation generic drug applicants by more than US$270,000 for fiscal year (FY) 2019 compared to 2018.

The increases were announced by FDA in a July 2018 Federal Register notice. Active pharmaceutical ingredient (API) manufacturers, on the other hand, will actually see a small decrease in fees and finished drug formulation (FDF) facilities remain almost the same. 

The fees come as part of the Generic Drug User Fee Amendments II (GDUFA II), which was approved by the US Congress on 18 August 2017 [1].

The FY 2019 fees for finished dosage form (FDF) and API facilities for US and foreign generics manufacturers, as well as the GDUFA programme and application fees, which are due on 1 October 2018, are:

 

2018 (US$)

2019 (US$)

Applications

 

 

ANDA

171,823

178,799

DMF

47,829

55,013

Facilities

 

 

Domestic API

45,367

44,226

Foreign API

60,367

59,226

Domestic FDF

211,087

211,305

Foreign FDF

226,087

226,305

GDUFA programme

 

 

Large-size operation generic drug applicant

1,590,792

1,862,167

Medium-size operation generic drug applicant

636,317

744,867

Small business operation generic drug applicant

159,079

186,217

Large-size operation generic drug applicant programme user fees increase by more than US$270,000. For medium-size operations, the fee is increasing by more than US$100,000 and for small operations the fee jumps by more than US$27,000. The agency is also increasing the fees for ANDA applications and drug master files (DMFs) by around US$7,000.

The extra cost for non-US manufacturers has been kept the same as in 2018, as being US$15,000 more than domestic facilities. This has been calculated by FDA to be sufficient to cover the higher costs of inspecting foreign facilities.

All applicants that submit an ANDA must pay the FY 2019 filing fee on or after 1 October 2018.

Related article
FDA issues final guidance on biosimilar user fees

Reference
1.  GaBI Online - Generics and Biosimilars Initiative. FDA issues final guidance on ANDA/PAS amendments [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Sep 7]. Available from: www.gabionline.net/Guidelines/FDA-issues-final-guidance-on-ANDA-PAS-amendments

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Source: Federal Register, US FDA

Comments (0)